SCHEMBL20558667

SCHEMBL20558667

COC(=O)c1ccc(Cl)c2c1OCC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 5/20 0.40
SLC6A2 P23975 3/20 0.40
ABL1 P00519 1/20 0.40
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 2/20 0.38
LMNA P02545 2/20 0.38
SLC6A4 P31645 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HTR4 Q13639 2/20 0.38
HTR1A P08908 1/20 0.38
ADRA2C P18825 1/20 0.38
ACHE P22303 1/20 0.38
PTGS1 P23219 1/20 0.38
ADRA1A P35348 1/20 0.38
HTR3A P46098 1/20 0.38
KCNH2 Q12809 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
NOTUM Q6P988 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15898897 0.83 CA12 (0.44) KDM4EALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL19125590 0.83 MAOA (0.42) KDM4EALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL15502345 0.83 KDM4E (0.47) SLC6A3ABL1KDM4EALDH1A1LMNA
SCHEMBL22032173 0.82 KDM4E (0.38) SLC6A3KDM4EALDH1A1LMNAHSD17B10
SCHEMBL14320278 0.82 KDM4E (0.48) ABL1KDM4EALDH1A1LMNAHSD17B10
SCHEMBL13385014 0.80 KDM4E (0.42) SLC6A3SLC6A2ABL1KDM4EALDH1A1
SCHEMBL34464425 0.79 ALDH1A1 (0.38) KDM4EALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL34464484 0.79 KDM4E (0.36) KDM4EALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL31321104 0.79 ALDH1A1 (0.40) KDM4EALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL5042523 0.78 HTR4 (0.54) KDM4EALDH1A1HTR4HTR1AADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115232144-B Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof 长春金赛药业有限责任公司 2024-04-02 CN disclosed
WO-2023222124-A1 5,6-DIHYDRO-1,2,4-TRIAZINE COMPOUND AND PHARMACEUTICAL USE THEREOF AS GLP-1 RECEPTOR AGONIST 中国科学院上海药物研究所 2023-11-23 WO disclosed
CN-115521297-A 5,6-dihydro-1,2,4-triazines and their pharmaceutical use as GLP-1 receptor agonists 中国科学院上海药物研究所 2022-12-27 CN disclosed
CN-115232144-A Nitrogen-containing fused ring derivative, pharmaceutical composition, preparation method and application thereof 长春金赛药业有限责任公司 2022-10-25 CN disclosed
CN-114716423-A 5, 6-dihydro-1, 2, 4-triazines and their pharmaceutical use as GLP-1 receptor agonists 中国科学院上海药物研究所 2022-07-08 CN disclosed
CN-108699098-B C-glucoside derivative having fused benzene ring or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition comprising same 第一药品株式会社 2022-01-25 CN disclosed
US-10752604-B2 C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same Je II Pharmaceutical Co., Ltd. (KR) 2020-08-25 US disclosed
US-10752604-B2 C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same Je II Pharmaceutical Co., Ltd. (KR) 2020-08-25 US disclosed
EP-3404033-B1 C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME JEIL PHARMACEUTICAL CO LTD (KR) 2020-08-05 EP disclosed
EP-3404033-B1 C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME JEIL PHARMACEUTICAL CO LTD (KR) 2020-08-05 EP disclosed
US-20190002425-A1 C-Glucoside Derivative Containing Fused Phenyl Ring or Pharmaceutically Acceptable Salt Thereof, Process for Preparing Same, and Pharmaceutical Composition Comprising Same JE IL PHARMACEUTICAL CO., LTD. (KR) 2019-01-03 US disclosed
US-20190002425-A1 C-Glucoside Derivative Containing Fused Phenyl Ring or Pharmaceutically Acceptable Salt Thereof, Process for Preparing Same, and Pharmaceutical Composition Comprising Same JE IL PHARMACEUTICAL CO., LTD. (KR) 2019-01-03 US disclosed
EP-3404033-A1 C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Jeil Pharmaceutical Co., Ltd. (KR) 2018-11-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190002425-A1 C-Glucoside Derivative Containing Fused Phenyl Ring or Pharmaceutically Acceptable Salt Thereof, Process for Preparing Same, and Pharmaceutical Composition Comprising Same SLC5A2, SLC5A1, UGGT1 SLC6A3 61/4885SLC6A2 60/4885ABL1 1561/4885
US-10752604-B2 C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same SLC5A2, SLC5A1, UGGT1 SLC6A3 61/4885SLC6A2 60/4885ABL1 1561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.